Patent details
LUC00340 Product Name: omavéloxolone ou un de ses sels pharmaceutiquement acceptables
Basic Information
- Publication number:
- LUC00340
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP137207080
- Legal Status:
- Pending & Published
- Application number:
- LUC00340
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/23/1786
- Marketing Authorization Type:
- Marketing Authorization Date:
- 12/02/2024
- Marketing Authorization Status:
- Claimed
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 18/04/2024
- First Marketing Authorization date:
- 12/02/2024
- Grant date:
- Activation date:
- Publication date:
- 18/04/2024
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 24/04/2038
- SPC Extension Expiration:
- 24/04/2038
- Rejection date:
- Withdrawal date:
Owner
- From:
- 18/04/2024
- Name:
- REATA PHARMACEUTICALS HOLDINGS, LLC
- Address:
- 5320 Legacy Drive, Plano, 75024, Texas, Texas, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 18/04/2024
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2024/06
- Publication date:
- 06/05/2024
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
| Filing date | Document type | Number of pages |
|---|---|---|
| 18/04/2024 | Outgoing Correspondence | 1 |
| 18/04/2024 | Publication | 1 |
| 18/04/2024 | Application Form | 3 |
| 18/04/2024 | Summary of the product caracteristics | 34 |
| 18/04/2024 | General Document | 2 |
| 18/04/2024 | Marketing authorization | 3 |
| 18/04/2024 | MA publication | 9 |